Anumana’s AI tool for pulmonary hypertension gets FDA breakthrough status
Related Articles
Anumana to Share Latest Advances in ECG-AI at AHA Scientific Sessions 2025
Company to present four studies, including a late-breaking featured science presentation, and host interactive experiences demonstrating AI’s role in cardiovascular careNovember 05, 2025
Mayo Clinic AI algorithm proves effective at spotting early-stage heart disease in routine EKG data
FIERCE Biotech: An algorithm developed by the Mayo Clinic can significantly increase the number of cases of low ejection fraction caught in its earliest stages, when it’s still most treatable,…May 09, 2022
How Mayo Clinic is using AI to spot hidden heart conditions
Advisory Board: Mayo Clinic last month released a study suggesting that an artificial intelligence (AI) algorithm could be used to better diagnose a certain heart condition called low ejection fraction—one step…May 31, 2021
Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
Mass Device: Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm. Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in…May 23, 2022